Janus Henderson Group Portfolio holdings
Janus Henderson Group, formed in 2017 through the merger of Janus Capital Group (founded 1969) and Henderson Group (founded 1934), is a global asset management firm headquartered in London, managing over $350 billion in assets as of late 2024 for institutional, retail, and high-net-worth clients. With a strong presence in the U.S., Europe, and Asia-Pacific, the firm offers a wide range of investment products, including equities, fixed income, multi-asset, and alternative strategies, often blending active management with research-driven insights. Known for its equity expertise from Janus’s growth-focused heritage and Henderson’s European fixed-income strengths, Janus Henderson serves clients through mutual funds, ETFs, and bespoke portfolios, emphasizing risk-adjusted returns and ESG integration. Led by CEO Ali Dibadj since 2022, the publicly traded firm (NYSE: JHG) continues to refine its strategy amid competitive pressures, maintaining a foothold in key markets worldwide.
Top Buys
| 1 |
Linde
LIN
|
+$588M |
| 2 |
Apple
AAPL
|
+$574M |
| 3 |
Illumina
ILMN
|
+$398M |
| 4 |
argenx
ARGX
|
+$306M |
| 5 |
CTLT
CATALENT, INC.
CTLT
|
+$250M |
Top Sells
| 1 |
Meta Platforms (Facebook)
META
|
+$600M |
| 2 |
AbbVie
ABBV
|
+$323M |
| 3 |
Sherwin-Williams
SHW
|
+$309M |
| 4 |
Atlassian
TEAM
|
+$250M |
| 5 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$241M |
Sector Composition
| 1 | Technology | 31.85% |
| 2 | Healthcare | 19.69% |
| 3 | Industrials | 10.43% |
| 4 | Financials | 10.02% |
| 5 | Consumer Discretionary | 9.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
2201
OneSpaWorld
OSW
$2.23B
| $354K | ﹤0.01% |
29,523
+16,547
| +128% | +$198K |
|
2202
Ares Management
ARES
$39B
| $353K | ﹤0.01% |
4,237
+28
| +0.7% | +$2.34K |
|
2203
Medical Properties Trust
MPW
$2.78B
| $353K | ﹤0.01% |
42,835
+27
| +0.1% | +$222 |
|
|
CSII
2204
DELISTED
Cardiovascular Systems, Inc.
CSII
| $353K | ﹤0.01% |
+17,756
| New | +$353K |
|
2205
MRC Global
MRC
$1.24B
| $352K | ﹤0.01% |
36,192
+20,335
| +128% | +$198K |
|
2206
Zymeworks
ZYME
$1.16B
| $351K | ﹤0.01% |
+38,894
| New | +$351K |
|
2207
Banc of California
BANC
$2.65B
| $351K | ﹤0.01% |
+28,024
| New | +$351K |
|
2208
Petco
WOOF
$1.02B
| $349K | ﹤0.01% |
38,777
+21,937
| +130% | +$198K |
|
|
CSR
2209
Centerspace
CSR
$988M
| $349K | ﹤0.01% |
+6,386
| New | +$349K |
|
2210
indie Semiconductor
INDI
$800M
| $348K | ﹤0.01% |
33,011
+17,689
| +115% | +$187K |
|
|
SP
2211
DELISTED
SP Plus Corporation
SP
| $347K | ﹤0.01% |
+10,119
| New | +$347K |
|
2212
Twist Bioscience
TWST
$1.51B
| $346K | ﹤0.01% |
22,933
+13,064
| +132% | +$197K |
|
2213
National Grid
NGG
$69.9B
| $344K | ﹤0.01% |
5,296
| – | – |
|
|
RTL
2214
DELISTED
The Necessity Retail REIT, Inc. Class A Common Stock
RTL
| $344K | ﹤0.01% |
54,834
+32,573
| +146% | +$204K |
|
2215
Sinclair Inc
SBGI
$921M
| $344K | ﹤0.01% |
+20,015
| New | +$344K |
|
2216
1st Source
SRCE
$1.57B
| $343K | ﹤0.01% |
+7,947
| New | +$343K |
|
2217
Enanta Pharmaceuticals
ENTA
$191M
| $341K | ﹤0.01% |
+8,452
| New | +$341K |
|
2218
Viridian Therapeutics
VRDN
$1.64B
| $341K | ﹤0.01% |
+13,414
| New | +$341K |
|
2219
Oil States International
OIS
$333M
| $341K | ﹤0.01% |
+40,893
| New | +$341K |
|
2220
James River Group
JRVR
$240M
| $340K | ﹤0.01% |
+16,445
| New | +$340K |
|
|
RWT
2221
Redwood Trust
RWT
$793M
| $339K | ﹤0.01% |
50,298
+27,481
| +120% | +$185K |
|
2222
Scansource
SCSC
$935M
| $337K | ﹤0.01% |
+11,087
| New | +$337K |
|
|
AHH
2223
Armada Hoffler Properties
AHH
$579M
| $337K | ﹤0.01% |
28,543
+16,452
| +136% | +$194K |
|
2224
Tootsie Roll Industries
TR
$2.88B
| $337K | ﹤0.01% |
+7,959
| New | +$337K |
|
2225
Arcus Biosciences
RCUS
$1.2B
| $334K | ﹤0.01% |
+18,341
| New | +$334K |
|